Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Pierre Fabre Medicament
Pierre Fabre Medicament S a s

Pierre Fabre Medicament patents


Recent patent applications related to Pierre Fabre Medicament. Pierre Fabre Medicament is listed as an Agent/Assignee. Note: Pierre Fabre Medicament may have other listings under different names/spellings. We're not affiliated with Pierre Fabre Medicament, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "P" | Pierre Fabre Medicament-related inventors


Derivatives of macrocyclic n-aryl-2-amino-4-aryl-pyrimidine polyethers as inhibitors of ftl3 and jak

The present invention relates to a compound with the following formula: formula (I) or a salt and/or a pharmaceutically acceptable solvate thereof, in particular for use as a drug, in particular in the treatment of cancer, as well as to the pharmaceutical compositions that contain same and to the methods... Pierre Fabre Medicament

Derivatives of macrocyclic n-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of ftl3 and jak

The present invention relates to a compound with the following formula (I): (I) or a salt and/or a pharmaceutically acceptable solvate thereof, in particular for use as a drug, in particular in the treatment of cancer, as well as to the pharmaceutical compositions that contain same and to the methods... Pierre Fabre Medicament

Igf-1r antibody and its use as addressing vehicle for the treatment of cancer

The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to IGF-1R... Pierre Fabre Medicament

Method for treating movement disorders with befiradol

The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, where in the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration,... Pierre Fabre Medicament

Isoquinolinone derivatives useful in the treatment of cancer

The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as a drug, notably in the treatment of cancer, as well as pharmaceutical compositions containing such a compound and processes to prepare such a compound.... Pierre Fabre Medicament

Novel anti-cxcr4 antibody and its use for the detection and diagnosis of cancer

The present invention provides a novel, isolated anti-CXCR4 antibody for use in the diagnosis of cancer. In particular, the antibody of the invention recognizes monomeric and homodimeric CXCR4, but not heterodimeric CXCR4... Pierre Fabre Medicament

Anti-cmet antibody

The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.... Pierre Fabre Medicament

Flavagline derivatives

The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention... Pierre Fabre Medicament

Conjugate of monomethyl auristatin f and trastuzumab and its use for the treatment of cancer

The present invention relates to an antibody-drug-conjugate or pharmaceutical composition comprising the same. From one aspect, the invention relates to an antibody-drug-conjugate (ADC) comprising an antibody consisting of the Trastuzumab or a biosimilar thereof, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative.... Pierre Fabre Medicament

Aminocyclobutane derivatives, preparing same and the use thereof as drugs

R2 represents independently or together a methyl group or ethyl group.... Pierre Fabre Medicament

Igf-1r antibody-drug-conjugate and its use for the treatment of cancer

The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method... Pierre Fabre Medicament

Antibody-drug-conjugate and its use for the treatment of cancer

The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and... Pierre Fabre Medicament








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Pierre Fabre Medicament in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Pierre Fabre Medicament with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###